Drug Trial Radar · NCT00313313
A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas
Last checked: Nov 20, 2026Latest source record: May 4, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
768
Actual
Start
Apr 2006
Primary completion
Sep 2007
Study completion Sep 2008
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Apr 12, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 77 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to understand if adding saxagliptin to a sulfonylurea is safe and works better than increasing the amount of sulfonylurea a patient takes
Conditions
- Diabetes
Interventions
SaxagliptinDrug
Tablets, Oral, 2.5 mg, Daily AM, (24 weeks short-term \[ST\], 12 months long-term \[LT\])
SaxagliptinDrug
Tablets, Oral, 5 mg, Daily AM (24 weeks ST, 12 months LT).
GlyburideDrug
Capsules, Oral, OL, 7.5 mg, Daily, AM (24 weeks ST, 12 months LT)
PlaceboDrug
Tablets, Oral, 0 mg, Daily AM/PM, (24 weeks ST, 12 months LT)
GlyburideDrug
Capsules, Oral, DB Glyburide, 2.5 mg titrated to 7.5 mg + 7.5 mg OL, Daily AM/PM (24 weeks ST, 12 months LT)
MetforminDrug
Tablets, Oral, OL, 500 - 2500 mg, 1 or 2 times per day (12 months LT)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Hemoglobin A1c (A1C) at Week 24Time frame: Baseline, Week 24
Locations
115 sites in 13 countries. Site status is shown where the registry gives one.
Reserach Solutions, Llc
Jonesboro, Arkansas
Searcy Medical Center
Searcy, Arkansas
Stewart Medical Group
Alhambra, California
Southland Clinical Research Center, Inc.
Fountain Valley, California
Valley Research
Fresno, California
Randall Shue, D.O.
Los Angeles, California
Clinical Trials Research
Roseville, California
New West Physicians
Golden, Colorado
Phoenix Internal Medicine Associates, Llc
Waterbury, Connecticut
Christiana Care Research Institute
Newark, Delaware
Central Florida Clinical Trials
Altamonte Springs, Florida
Family Care Assoc & Emerald Care Res Grp
Chipley, Florida
Clinical Therapeutics Corporation
Coral Gables, Florida
Fpa Clinical Research
Kissimmee, Florida
Emerald Coast Research Group
Marianna, Florida
University Of Miami Diabetes Research Inst.
Miami, Florida
Atlanta Pharmaceutical Research Center, Inc
Dunwoody, Georgia
Cedar-Crosse Research Ctr
Chicago, Illinois
Family Medical Center Of Hart Co.
Munfordville, Kentucky
Columbia Medical Practice
Columbia, Maryland
Va Medical Center
Kansas City, Missouri
St. Louis Center For Clinical Research
St Louis, Missouri
Nevada Alliance Against Diabetes
North Las Vegas, Nevada
Physicians Research Center
Toms River, New Jersey
Cny Family Care
East Syracuse, New York
Metrolina Internal Medicine
Charlotte, North Carolina
Med Res Assoc Charlotte
Charlotte, North Carolina
Regional Physicians Research
High Point, North Carolina
Diabetes & Endocrinology Consultants, Pc
Morehead City, North Carolina
Mountain Top Clinical Research Center
Sparta, North Carolina
Daystar Clinical Research, Inc.
Akron, Ohio
Community Health Care
Canal Fulton, Ohio
Triphase Research, Ltd.
Franklin, Ohio
Albert J Weisbrot,Md&Assoc Inc
Mason, Ohio
Dr Bahagwan Dass Md
Youngstown, Ohio
Oklahoma Cardiovascular And Hypertension Center
Oklahoma City, Oklahoma
Utica Park Clinic
Tulsa, Oklahoma
Integris Family Care Yukon
Yukon, Oklahoma
Coordinators Plus, Llc
Eugene, Oregon
Oregon Clinical Research
Portland, Oregon
Showing 40 of 115 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.